Subtype
Malignant Uterine Neoplasm
CI-CAN-00005955Explore in graph →
824 active trials7 approved drugs44 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005955Explore in graph →
Clinical trials
3,291 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (333)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04291612 | Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | recruiting | — | 1,715 | Memorial Sloan Kettering Cancer CenterOTHER | 5 | Aug 7, 2026 | clinicaltrials |
| NCT05673252 | CERvical Cancer The InFlammatory Index (CERTIFIKO)(CERTIFIKO) | active not recruiting | — | 128 | University of Campania Luigi VanvitelliOTHER | 1 | Aug 7, 2026 |
| clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT07038369 | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | active not recruiting | Phase 1 | 134 | Atavistik Bio, IncINDUSTRY | 4 | Aug 7, 2026 | clinicaltrials |
| NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | not yet recruiting | Phase 1 / Phase 2 | 250 | LG ChemINDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT05226507 | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer | terminated | Phase 1 | 45 | Nuvectis Pharma, Inc.INDUSTRY | 2 | Aug 6, 2026 | clinicaltrials |
| NCT05581004 | A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 165 | Genentech, Inc.INDUSTRY | 10 | Aug 6, 2026 | clinicaltrials |
| NCT07716735 | Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer | not yet recruiting | Phase 1 | 18 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06607874 | Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida | not yet recruiting | — | 100 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07059884 | Distance-Based Exercise to Preserve Function and Prevent Disability(DEFEND) | recruiting | N/A | 104 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07281547 | Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain | not yet recruiting | Phase 4 | 20 | Mayo ClinicOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07444814 | Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 226 | Whitehawk Therapeutics, Inc.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07684508 | Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer | recruiting | N/A | 154 | Manni HuangOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07746349 | Terlipressin vs Placebo to Reduce Bleeding in Fibroid Surgery | not yet recruiting | N/A | 80 | Sevil CankayaOTHER | 0 | Aug 5, 2026 | clinicaltrials |
| NCT04739800 | Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents | active not recruiting | Phase 2 | 120 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05111574 | Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery | active not recruiting | Phase 2 | 101 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05554328 | Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | active not recruiting | Phase 2 | 165 | National Cancer Institute (NCI)NIH | 2 | Aug 4, 2026 | clinicaltrials |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)(RAINFOL-01) | recruiting | Phase 1 / Phase 2 | 884 | GenmabINDUSTRY | 3 | Aug 4, 2026 | clinicaltrials |
| NCT07743918 | Vitamin D Status and Clinical Outcomes in Locally Advanced Cervical Cancer(CERVITAL) | recruiting | — | 100 | University of KragujevacOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07746024 | Advancing Risk Stratification in Endometrial Cancer(DaPHNE) | active not recruiting | — | 400 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05603910 | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | recruiting | Phase 1 | 18 | Aaron WolfsonOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT06096688 | Discovering New Targets for Colorectal and Endometrial Cancer Risk Reduction | recruiting | — | 1,120 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02595879 | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03914612 | Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | active not recruiting | Phase 3 | 813 | National Cancer Institute (NCI)NIH | 5 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT04927494 | Cervical Cancer Prevention for Black Adults | completed | N/A | 288 | Adebola AdegboyegaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05283421 | Improving Diagnostics in Cervical Dysplasia(IDEAL) | recruiting | N/A | 150 | University of AarhusOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07209917 | Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India(SAKHI) | recruiting | N/A | 348 | University of California, IrvineOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07259304 | Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | active not recruiting | — | 118 | University of Southern CaliforniaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07281430 | Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S04) | recruiting | N/A | 500 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07419841 | A Phase 1 Study of the Safety and Tolerability of CTX-10726 | recruiting | Phase 1 | 70 | Compass TherapeuticsINDUSTRY | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07738315 | Elemene Liposomes in Endometrial Cancer | not yet recruiting | Phase 2 | 212 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07739745 | Development Of An Endometrial Cancer Educational Tool | not yet recruiting | N/A | 250 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT01797523 | A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma | completed | Phase 2 | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03526432 | Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer | active not recruiting | Phase 2 | 110 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04657068 | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 542 | Artios Pharma LtdINDUSTRY | 4 | Jul 30, 2026 | clinicaltrials |
| NCT04831580 | A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer(ROCC) | recruiting | N/A | 840 | GOG FoundationNETWORK | 4 | Jul 30, 2026 | clinicaltrials |
| NCT05047913 | Comprehensive Evaluation of Tumor Oxygenation, Metabolism and Blood Supply of High Grade Glioma and Cervical Cancers Using Dynamic FAZA PET and Multiparametric MR | active not recruiting | Early Phase 1 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06715241 | A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS(COLIBRI-2) | active not recruiting | Phase 2 | 77 | ARCAGY/ GINECO GROUPOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06786429 | Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health. | not yet recruiting | Phase 4 | 2,140 | Eunice DubeOTHER | 0 | Jul 30, 2026 | clinicaltrials |
| NCT07730970 | Deep Neuromuscular Blockade and a Low-Residue Diet for the Surgical Field in vNOTES Hysterectomy(vNOTES_NMBDIET) | recruiting | N/A | 160 | Fatih Sultan Mehmet Training and Research HospitalOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | not yet recruiting | Phase 2 | 66 | University of OklahomaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT03538665 | The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons(DETECT) | recruiting | — | 1,700 | University of Alabama at BirminghamOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | terminated | Phase 2 | 35 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06486441 | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)(ASCENT-GYN-01) | active not recruiting | Phase 3 | 640 | Gilead SciencesINDUSTRY | 19 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT07200466 | Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation(ENDORISK-I) | recruiting | N/A | 735 | Radboud University Medical CenterOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02912572 | Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer | active not recruiting | Phase 2 | 106 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | recruiting | Phase 3 | 710 | Daiichi SankyoINDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 7, 2026source: clinicaltrials